Heritage Investors Management Corp cut its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 10.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,122 shares of the biopharmaceutical company’s stock after selling 14,721 shares during the quarter. Heritage Investors Management Corp’s holdings in Bristol Myers Squibb were worth $7,037,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in BMY. Journey Advisory Group LLC increased its holdings in shares of Bristol Myers Squibb by 1.2% in the 2nd quarter. Journey Advisory Group LLC now owns 17,141 shares of the biopharmaceutical company’s stock valued at $988,000 after purchasing an additional 200 shares in the last quarter. TD Asset Management Inc boosted its stake in shares of Bristol Myers Squibb by 51.4% during the 2nd quarter. TD Asset Management Inc now owns 2,007,448 shares of the biopharmaceutical company’s stock worth $115,669,000 after acquiring an additional 681,472 shares in the last quarter. SmartHarvest Portfolios LLC increased its stake in Bristol Myers Squibb by 83.1% in the 2nd quarter. SmartHarvest Portfolios LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 2,741 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Bristol Myers Squibb during the second quarter worth $84,000. Finally, Ascent Group LLC increased its position in shares of Bristol Myers Squibb by 46.4% in the second quarter. Ascent Group LLC now owns 55,716 shares of the biopharmaceutical company’s stock valued at $3,210,000 after buying an additional 17,649 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
BMY has been the topic of a number of research reports. TD Cowen started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Royal Bank Of Canada increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Finally, Raymond James Financial initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.
Bristol Myers Squibb Trading Down 1.2%
Bristol Myers Squibb stock opened at $63.86 on Friday. The stock has a market cap of $130.45 billion, a PE ratio of 14.07, a P/E/G ratio of 0.17 and a beta of 0.22. The stock has a 50-day moving average price of $59.56 and a 200 day moving average price of $58.97. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.10. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.
Bristol Myers Squibb Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.
Key Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
- Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
- Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
- Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
- Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
